You searched for "disease"
Prostate Cancer: 'A Marathon, Not a Sprint' Podcast
Men Only was established to offer a platform for men to openly discuss issues important to them. This platform provides a safe space for open dialogue and exploration of topics that are frequently marginalised in mainstream conversations. The platform aims...Fournier’s gangrene
Introduction Fournier’s gangrene (FG) is a rare but fulminant form of infective necrotising fasciitis affecting the perineum and external genitalia, which can rapidly progress along fascial planes. It most commonly affects men, but can occur in women and children, with...Recent developments in bladder cancer – NMIBC
Every year, roughly 10,300 individuals are diagnosed with bladder cancer in the UK, making it the 11th most common cancer in the UK, and the eighth most common cancer in men [1]. Of those diagnosed with the disease, 75-85% will...
Oncological benefits of extended pelvic lymph node dissection
Touijer and colleagues present extended follow-up results from a large randomised trial comparing limited pelvic lymph node dissection (l-PLND) and extended PLND (e-PLND) in prostate cancer patients undergoing radical prostatectomy. The study aimed to assess whether e-PLND, which includes external...How to set up and run a cadaveric dissection course
Conducting and implementing a cadaveric dissection course requires careful planning. Rachel Edmiston, Rajesh Anmolsingh, Omar Mirza and Nirmal Kumar offer a guide to individuals highlighting the licensing and legal processes involved with the use, preservation and disposal of cadavers in...
Long-term oncologic outcomes of salvage cryoablation for rrPC
Of patients undergoing radiotherapy (RT) for prostate cancer (PC), at least 15-20% will experience recurrence. Although salvage prostatectomy achieves durable oncological outcomes at 10 years, it is associated with significantly high morbidity. Thus, the majority of men with radio-recurrent prostate...
Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?
Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...
